SCHOENFELD RYAN CRAIG,DE VICENTE FIDALGO JAVIER,TALAMAS FRANCISCO XAVIER,TAYGERLY JOSHUA PAUL GERGELY,LI JIM
申请号：
NZ59664610
公开号：
NZ596646A
申请日:
2010.06.08
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
596646 Disclosed herein are compounds of the formula (I), wherein the variables are defined in the specification, for use in the treatment of a HCV infection, optionally in combination with at least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV. Preferred embodiments of the compounds include the following: N-{ 4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1,2-dihydro-pyridin-3-yl)-quinolin-3-yl]-but-3-ynyl} -methanesulfonamide； N-{ (E)-4-[6-tert-butyl-8-(dioxo-tertahydro-pyrimidin-1-yl)-quinolin-3-yl]-phenyl} -methanesulfonamine； and N-{ (S)-1-[6-tert-butyl-8-(6-hydroxymethyl-2-oxo-1,2-dihydro-pyridin-3-yl)-5-methoxy-quinolin-3-yl]-pyrrolidin-3-ylmethyl} -methanesulfonamide.
